InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,528.93
(
-2.12%
)
US TECH 100
18,424.00
(
-3.29%
)
Dow Jones
40,936.93
(
-1.51%
)
Brent Oil
73.19
(
-0.59%
)
Bitcoin
56,714.01
(
-1.23%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

NP1986

Send PM Follow Ignore
Followers 6
Posts 541
Boards Moderated 0
Alias Born 06/07/2011

NP1986

Re: Maciste post# 12169

Monday, 08/22/2011 11:10:11 PM

Monday, August 22, 2011 11:10:11 PM

Post# of 80490
I've purchased ARIA shares just in the last few months so I am in the same boat as you. It was nice when it was in the $13's, but I'm a strong believer in ponatinib's potential and so will not sell until that story develops further.

I also have INCY shares which are in the red and likely to be for some time, but I see quite a bit of potential in their JAK inhibitor program so am holding on to them.

Both ARIA and INCY are down today, but so is the NASDAQ biotech index (NBI). However, this short-term volatility will mean little if ponatinib is approved.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up